MHRA has reviewed how risk information is communicated for gabapentinoids, benzodiazepines, and z-drugs and concluded that warnings on these medicines need to be strengthened. The agency said it was necessary to improve the warnings regarding addiction, dependence, withdrawal, and tolerance in the product information and on packaging so that healthcare professionals and patients are better informed of these known risks.
MHRA said the Summary of Product Characteristics, Patient Information Leaflets, and outer packaging for these medicines will be updated, with changes being rolled out over the coming months. The agency also said that before starting treatment, healthcare professionals should discuss a strategy for reducing or ending treatment with patients, and that abrupt cessation or dose reduction can trigger drug withdrawal syndrome.
The review was not narrow. MHRA said it drew on UK Yellow Card data, company data, information from other international regulators, GP practice data, and lived-experience accounts from patient charity groups and professional stakeholders. It concluded that existing wording did not sufficiently communicate the extent of the known risks linked with these medicines.
MHRA also stressed that these risks can occur with prolonged use but may also arise with short-term use at recommended therapeutic doses, and that the risk is increased in people with a current or past history of substance misuse disorder or mental health disorder. The agency advised that patients should be monitored for signs of misuse, abuse, or addiction and that tapering plans should be individualized.
For pharmacovigilance professionals, this is a very strong example of postmarketing experience feeding back into risk communication strategy. The issue here was not the discovery of a completely unknown hazard. It was the conclusion that the communication of already-known risks was not strong or clear enough. That makes this a classic pharmacovigilance lesson: safety is not only about identifying risks, but also about ensuring those risks are communicated in a way that supports safer use.
The update also shows how regulator review can extend beyond data collection into practical tools for safer prescribing and discontinuation. MHRA says it has developed additional patient resources for these medicine classes and encourages use of wider prescribing and withdrawal guidance. That reinforces the idea that pharmacovigilance is most effective when it connects safety evidence to real-world behavior and decision-making.
Why this matters for PV professionals
This MHRA action shows how regulators use postmarketing evidence not only to assess risk, but to improve how risk is explained, understood, and acted on by both clinicians and patients.
0 Comments